South Asians (those from India, Pakistan, Bangladesh, Nepal, Bhutan, Sri Lanka, and the Maldives) represent a rapidly increasing population in the U.S. and have significant cardiometabolic risk. Current AHA/ACC Prevention Guidelines list South Asian ethnicity as a risk-enhancer for consideration of initiation of statin therapy. Given the high cardiometabolic risk in this population, I proposed and moderated a session at #AHA21 focused on the excess risk in South Asians. In this session, we learned several key concepts:
1) Compared to white individuals, South Asians have a twofold increased risk of coronary heart disease. In addition, South Asians manifest clinical coronary disease events 5-7 years earlier. This risk is independent of other risk factors and not fully explained by lifestyle.
2) South Asians also have a marked excess risk of diabetes, upward of 3-4 times the prevalence and incidence seen in white individuals.
3) The cardiometabolic features most associated with this excess risk include significant and premature insulin resistance despite a lack of generalized obesity; excess hepatic, visceral, and muscle fat deposition; and an atherogenic dyslipidemia with elevated triglycerides, low HDL-C, and small, dense LDL particles.
4) In South Asians, similar to other Asians, a BMI>23 signifies overweightness and increased risk for diabetes and cardiovascular disease. This is perhaps the easiest and most underappreciated metric for identifying South Asians at risk.